You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康辰藥業(603590.SH):中藥創新藥ZY5301臨牀研究結果榮登《JAMA》子刊
格隆匯 07-29 15:43

格隆匯7月29日丨康辰藥業(603590.SH)公佈,ZY5301是北京康辰藥業股份有限公司擁有自主知識產權的中藥創新藥,聚焦於治療女性盆腔炎性疾病後遺症慢性盆腔痛的臨牀研究。近期,ZY5301Ⅱ期臨牀研究結果(CTR20202153)在經多位國際評審專家嚴苛審評後,《JAMANetworkOpen》正式接受並以“ZY5301TabletvsPlaceboforTreatmentofChronicPelvicPainAfterPelvicInflammatoryDisease:APhase2RandomizedClinicalTrial”刊出。

《美國醫學會雜誌(JAMA)》是國際權威頂尖醫學期刊,《JAMANetworkOpen》為其子刊,2022年影響因子13.8,ZY5301Ⅱ期臨牀研究結果在其刊出,不僅體現了國際期刊對ZY5301Ⅱ期臨牀研究的科學性、嚴謹性的高度認可,還體現了其對治療女性盆腔炎性疾病後遺症慢性盆腔痛的有效性與安全性的高度認可。這是《JAMA》系列期刊首次刊登中國中藥在該治療領域的臨牀研究結果。首都醫科大學附屬北京中醫醫院滕秀香教授是該文的共同第一作者和通訊作者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account